Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -41.56% | -20.07% | -27.73% | -8.56% | -11.37% |
| Total Depreciation and Amortization | -48.93% | -82.73% | -95.35% | -92.36% | -91.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 559.23% | 2,490.43% | 282.43% | 163.76% | 156.34% |
| Change in Net Operating Assets | -68.78% | -61.14% | -91.61% | -58.53% | -19.18% |
| Cash from Operations | -13.87% | 2.96% | -8.31% | 3.56% | 4.73% |
| Capital Expenditure | 91.99% | 96.17% | 89.49% | 75.53% | -312.95% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 91.99% | 96.17% | 89.49% | -100.75% | -101.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -26.28% | 126.72% | 91.31% | 97.43% | 106.70% |
| Issuance of Common Stock | 136.34% | 180.05% | 317.90% | -52.62% | -69.58% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -358.16% | -488.56% | -136.60% | -1,025.24% | -329.82% |
| Cash from Financing | 111.14% | 170.41% | 272.59% | -45.82% | -60.80% |
| Foreign Exchange rate Adjustments | 118.42% | 203.33% | -2,082.05% | -338.68% | -987.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 58.92% | 63.40% | 51.63% | -268.47% | -220.60% |